regulatory
confidence high
sentiment positive
materiality 0.60
FDA grants Fast Track Designation to Quoin's QRX003 for Netherton Syndrome
Quoin Pharmaceuticals, Ltd.
- Fast Track Designation granted to QRX003 lotion (4%) for Netherton Syndrome, a rare genetic skin disorder with no approved treatments.
- QRX003 is currently in two late-stage whole-body clinical trials evaluating safety and efficacy in Netherton Syndrome patients.
- Previous designations include Orphan Drug Designation from FDA and EMA, and Pediatric Rare Disease Designation from FDA.
- Fast Track enables more frequent FDA interactions, rolling review, and potential Accelerated Approval or Priority Review.